LifeMD Target of Unusually High Options Trading (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) saw some unusual options trading on Tuesday. Investors bought 3,113 call options on the stock. This represents an increase of approximately 184% compared to the typical daily volume of 1,097 call options.

Wall Street Analysts Forecast Growth

LFMD has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a report on Tuesday, March 11th. KeyCorp cut their price objective on shares of LifeMD from $10.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. B. Riley raised LifeMD to a "strong-buy" rating in a research report on Tuesday, March 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price target on shares of LifeMD in a report on Wednesday. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $11.00.

LifeMD Stock Performance

Shares of NASDAQ:LFMD traded down $0.05 during midday trading on Friday, reaching $7.39. 242,757 shares of the company's stock were exchanged, compared to its average volume of 912,025. The company's 50 day simple moving average is $5.52 and its two-hundred day simple moving average is $5.55. LifeMD has a 12 month low of $3.99 and a 12 month high of $12.88. The firm has a market capitalization of $329.48 million, a PE ratio of -11.70 and a beta of 2.22.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The business had revenue of $64.26 million for the quarter, compared to the consensus estimate of $57.43 million. On average, research analysts anticipate that LifeMD will post -0.56 earnings per share for the current year.

Insider Buying and Selling at LifeMD

In related news, CEO Justin Schreiber sold 50,000 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $7.55, for a total value of $377,500.00. Following the transaction, the chief executive officer now directly owns 2,653,715 shares in the company, valued at approximately $20,035,548.25. This trade represents a 1.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CMO Jessica Friedeman sold 30,000 shares of LifeMD stock in a transaction on Friday, March 14th. The stock was sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the transaction, the chief marketing officer now owns 170,000 shares in the company, valued at $962,200. This trade represents a 15.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 130,000 shares of company stock worth $936,300 over the last 90 days. Insiders own 15.97% of the company's stock.

Institutional Trading of LifeMD

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC acquired a new stake in shares of LifeMD in the 1st quarter valued at $35,000. CWM LLC lifted its holdings in LifeMD by 17.5% during the 1st quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after purchasing an additional 1,351 shares during the last quarter. ProShare Advisors LLC acquired a new position in LifeMD in the fourth quarter valued at about $51,000. Oxford Asset Management LLP bought a new stake in LifeMD during the fourth quarter worth about $52,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of LifeMD during the fourth quarter worth approximately $52,000. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.